QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inflammation and Neurodegeneration Research

Executive Summary: QNZ (EVP4593) is a small-molecule quinazoline derivative that inhibits the NF-κB signaling pathway with an IC50 of 11 nM in human Jurkat T cells (APExBIO). It blocks PMA/PHA-induced NF-κB activation and TNF-α production at nanomolar concentrations, demonstrating anti-inflammatory effects in preclinical models. QNZ is insoluble in water but dissolves in DMSO and ethanol under specific conditions. In neurodegeneration models, such as Drosophila Huntington’s disease (HD), QNZ attenuates motor decline without observed toxicity. This compound is a reference tool for precise NF-κB signaling pathway modulation and SOC inhibition in research workflows (Yang et al., 2025).

Biological Rationale

The NF-κB signaling pathway is a central regulator of inflammation, immune response, and cellular survival. Abnormal activation of NF-κB is implicated in chronic inflammatory conditions, infectious diseases, and neurodegenerative disorders. In osteomyelitis, persistent infection and local abscesses drive pathological fibrosis and impair antibiotic penetration (Yang et al., 2025). Macrophage-derived amphiregulin activates EGFR/mTOR/YAP signaling, promoting myofibroblast transition and furthering disease persistence. Pharmacological inhibition of key signaling axes, including NF-κB, is a validated strategy to modulate inflammation and improve disease outcomes. QNZ (EVP4593) targets the NF-κB pathway, providing a mechanistic handle for dissecting inflammatory and neurodegenerative pathologies (Advanced Insights Article).

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a quinazoline derivative identified through a luciferase reporter gene-based assay. The compound inhibits NF-κB transcriptional activation with high potency. In human Jurkat T cells, the IC50 for inhibition of PMA/PHA-induced NF-κB activation is 11 nM, and for TNF-α production is 7 nM. QNZ acts by preventing the translocation of NF-κB to the nucleus, thereby reducing transcription of pro-inflammatory genes (e.g., TNF-α, IL-1β). In neuronal cells, QNZ at 300 nM attenuates store-operated calcium entry (SOC), a process implicated in Huntington’s disease pathology (Neurodegeneration Application Article). The compound does not interfere with unrelated signaling pathways at effective concentrations, supporting its selectivity as an NF-κB inhibitor.

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB activation in Jurkat T cells with an IC50 of 11 nM (APExBIO, product data).
• Reduces PMA/PHA-induced TNF-α production in cellular assays with an IC50 of 7 nM (APExBIO, product data).
• Suppresses edema formation in the rat carrageenin-induced paw edema model, demonstrating in vivo anti-inflammatory effects (APExBIO, product data).
• Slows progressive motor decline in Drosophila Huntington’s disease models without toxicity at effective doses (Neurodegeneration Application Article).
• Pharmacological inhibition of related signaling axes (EGFR/mTOR) in bone marrow models alleviates fibrosis and improves antibiotic efficacy (Yang et al., 2025).
• QNZ is insoluble in water but soluble in ethanol (≥10.06 mg/mL with ultrasonic assistance) and DMSO (≥15.05 mg/mL), facilitating flexible laboratory preparation (APExBIO, product data).
• Experimental use at 300 nM in neuronal cultures attenuates SOC influx, offering mechanistic insight into HD pathology (Neurodegeneration Application Article).

This article extends the discussion in "Advanced Insights into NF-κB Inhibition and Disease Modeling" by providing updated quantitative benchmarks and solubility guidance across cell and animal models.

Applications, Limits & Misconceptions

QNZ (EVP4593) is widely used in preclinical studies of inflammation, immune response, and neurodegeneration. In Huntington’s disease models, QNZ is applied at nanomolar concentrations to dissect NF-κB-dependent and -independent mechanisms of neuroprotection. The compound is also relevant in the study of infection-driven fibrosis, as seen in osteomyelitis, where NF-κB pathway modulation is a therapeutic angle (Yang et al., 2025). QNZ is not recommended for long-term storage in solution, as degradation may affect reproducibility. It is not a direct antibiotic and should not be used as such. For optimal solubility, warming to 37°C and ultrasonic shaking are recommended. QNZ is supplied as a research-use-only reagent by APExBIO (SKU: A4217).

Common Pitfalls or Misconceptions

• QNZ does not replace antibiotics in infectious disease models; it modulates host inflammatory response, not bacterial viability.
• Long-term storage in solution can reduce compound activity—always prepare fresh aliquots and store dry at -20°C.
• Water-based solvents are ineffective; always dissolve QNZ in DMSO or ethanol for experimental use.
• High concentrations (>1 μM) may introduce off-target effects—strictly titrate to nanomolar ranges for pathway selectivity.
• QNZ is not suitable for clinical or veterinary therapeutic use; it is strictly for in vitro and in vivo research applications.

For additional guidance, "QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inflammation" offers practical workflows, while this article adds context on neurodegeneration and experimental boundaries.

Workflow Integration & Parameters

To integrate QNZ (EVP4593) into experimental workflows, dissolve the compound in DMSO (≥15.05 mg/mL) or ethanol (≥10.06 mg/mL) with ultrasonic assistance and warming to 37°C. Prepare aliquots and store at -20°C to minimize freeze–thaw cycles. For neuronal cultures, 300 nM QNZ is effective in attenuating SOC influx. Inflammatory assays in Jurkat T cells use 7–11 nM for robust NF-κB pathway inhibition. In vivo anti-inflammatory efficacy is observed in standard paw edema models. Always include relevant controls for solvent and pathway specificity. For further workflow optimization, "QNZ (EVP4593): Practical Strategies for Reliable NF-κB Inhibition" provides scenario-driven experimental advice, while this article emphasizes solubility and disease model integration.

Conclusion & Outlook

QNZ (EVP4593) is a potent, selective NF-κB inhibitor with validated anti-inflammatory and neuroprotective effects in both cellular and animal models. Its well-characterized solubility, storage requirements, and nanomolar efficacy make it a reference compound for dissecting NF-κB signaling in inflammation, infection-driven fibrosis, and neurodegeneration. As a research-use-only product from APExBIO, QNZ (EVP4593) continues to support innovation in immunology and neuroscience. Ongoing studies are expected to expand its utility in disease modeling and mechanistic pathway exploration (Yang et al., 2025).

For product details, specifications, and ordering, visit the QNZ (EVP4593) product page.